CG Oncology, Inc. (CGON)

Compare

29.21

+0.45

(+1.56%)

At close: 4:00:01 PM EST

29.63

+0.42

(+1.44%)

After hours: 5:34:48 PM EST

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000

GlobeNewswire 2 hours ago

CGON
+1.56%
CG Oncology Announces Pricing of Public Offering

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at

GlobeNewswire 3 days ago

CGON
+1.56%
CG Oncology Announces Proposed Public Offering

IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 7,300,000 shares of its common stock. Additionally,

GlobeNewswire 5 days ago

CGON
+1.56%
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBCSCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a

GlobeNewswire 10 days ago

CGON
+1.56%
CG Oncology announces data from Phase 3 BOND-003 trial

CG Oncology (CGON) announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer, NMBIC, unresponsive to Bacillus Calmette Guerin, BCG, demonstrating 74.5% of patients achieved a complete response, CR, at any time, after receiving treatment with cretostimogene as a single agent. The median duration of response, DOR, has not been reached but exceeds 27 months as of the data cutoff of September 30, 2024. These data will be presented today as a

TipRanks 10 days ago

CGON
+1.56%
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate

On Thursday, CG Oncology, Inc. (NASDAQ:CGON) revealed topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG). The trial demonstrated that 74.5% of patients (82 out of 110) achieved a complete response (CR) at any time after receiving treatment with cretostimogene as a single agent. The median duration of response (DOR) has not been reached but exceeds 27 months as of the data cutoff of Sept

Benzinga 11 days ago

CGON
+1.56%
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone b

GlobeNewswire 11 days ago

CGON
+1.56%
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer

GlobeNewswire 14 days ago

CGON
+1.56%
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress PostersIRVINE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that four Trials in Progress Posters highlighting cretost

GlobeNewswire 26 days ago

CGON
+1.56%
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

CG Oncology ( NASDAQ:CGON ) Third Quarter 2024 Results Key Financial Results Net loss: US$20.4m (loss widened by 17...

Simply Wall St. last month

CGON
+1.56%
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quart

GlobeNewswire last month

CGON
+1.56%
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the body of evidence supporting potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer – IRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-spari

GlobeNewswire last month

CGON
+1.56%
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

CGON
+1.56%
Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Cg Oncology Inc. (NASDAQ:CGON) stands against the other cancer stocks. Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one […]

Insider Monkey 3 months ago

CGON
+1.56%
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this c

GlobeNewswire 3 months ago

CGON
+1.56%
Bullish CG Oncology Insiders Loaded Up On US$5.06m Of Stock

Multiple insiders secured a larger position in CG Oncology, Inc. ( NASDAQ:CGON ) shares over the last 12 months. This...

Simply Wall St. 3 months ago

CGON
+1.56%
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimo

GlobeNewswire 4 months ago

CGON
+1.56%
Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week

Key Insights Significantly high institutional ownership implies CG Oncology's stock price is sensitive to their trading...

Simply Wall St. 4 months ago

CGON
+1.56%
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

- First Patient Dosed in Expanded Access Program and Enrollment Ongoing -IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that it has initiated an Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer

GlobeNewswire 5 months ago

CGON
+1.56%
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine and featured at ASCO 2024 – – 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint of the phase 2 study – IRVINE, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeu

GlobeNewswire 6 months ago

CGON
+1.56%

Performance Overview

Return	CGON	S&P 500
YTD	+0.72%	+27.34%
1-Year	+0.72%	+28.71%
3-Year	+0.72%	+28.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CG Oncology, Inc. (CGON)

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology announces data from Phase 3 BOND-003 trial

CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth

Cg Oncology Inc. (CGON): Short Seller Sentiment is Bearish on This Cancer Stock

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Bullish CG Oncology Insiders Loaded Up On US$5.06m Of Stock

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Institutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last week

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Performance Overview